Pentraxin-3 as a poor marker of fibrosis in metabolic dysfunction-associated steatotic liver disease among older adults: findings from the PolSenior2 substudy
IntroductionThe study aimed to assess the relationship between plasma pentraxin 3 (PTX-3) levels and the potential diagnosis of fibrosis in metabolic dysfunction-associated steatohepatitis (MASH) in older adults. This was assessed using the Fibrosis-4 index (FIB-4), NAFLD fibrosis score (NFS), and H...
Saved in:
| Main Authors: | Aleksander Jerzy Owczarek, Joanna Musialik, Adrian Stefański, Małgorzata Mossakowska, Katarzyna Zięba, Andrzej Więcek, Jerzy Chudek, Magdalena Olszanecka-Glinianowicz |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1445973/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pentraxin-3 and C-reactive protein plasma levels predict survival in older adults with or without metabolic syndrome – results of the PolSenior2 substudy
by: Aleksander J. Owczarek, et al.
Published: (2025-05-01) -
Evaluation of Metabolic Dysfunction-Associated Steatotic Liver Disease in Patients with Type 2 Diabetes Mellitus
by: Hilmi Erdem Sümbül, et al.
Published: (2025-03-01) -
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): the interplay of gut microbiome, insulin resistance, and diabetes
by: Ankita Dua, et al.
Published: (2025-08-01) -
Fibrosis status, extrahepatic multimorbidity and all-cause mortality in 53,093 women and 74,377 men with metabolic dysfunction associated steatotic liver disease (MASLD) in UK biobank
by: Qi Feng, et al.
Published: (2025-07-01) -
Dasatinib and Quercetin as Senolytic Drugs Improve Fat Deposition and Exhibit Antifibrotic Effects in the Medaka Metabolic Dysfunction-Associated Steatotic Liver Disease Model
by: Shunta Yakubo, et al.
Published: (2024-12-01)